Market Firming Up

The broad market firmed up this week as oil moved above $33 and earnings season brought a number of positive results. Facebook (FB) and Microsoft (MSFT) gave investors reason to stay long those stocks, while Under Armour (UA) showed that there’s still growth in apparel.

Bellweather stocks Honeywell (HON), 3M (MMM) and Caterpillar (CAT) reported results that suggested those stocks are cheap at current levels.

But there were a few disappointments too, most notably Amazon (AMZN) and Electronic Arts (EA), that are trading down early this morning. With the Fed sitting pat for now, and Q4 U.S. GDP coming in at 0.7% (0.8% was expected so this is just a little light), earnings season and oil are likely to continue to drive the market’s direction over the coming weeks.

Large caps were up 1.3% over the past week while small caps were up 1.4%. Value outperformed growth in both. The bounce in oil gave energy stocks a rare leadership position for the week, while utility stocks came in second, suggesting that on balance, investors remain cautious.

Technology, industrials and consumer stocks all delivered modest gains this week. But health care was a laggard and the biotech blues continue with decent results from Biogen (BIIB) failing to overpower disappointments from Celgene (CELG) and Incyte (INCY). Biotech has been especially pummeled in 2016, with the iShares Biotech ETF (IBB) down 22% year-to-date. There will be a point at which biotech is a screaming buy, and based on valuation, large caps looks close, but the trend is undeniably down. Individual names must have something very special going for them to justify new investment right now.

Tyler Laundon is Chief Analyst of Cabot Small-Cap Confidential. To read subscriber reviews of Cabot Small-Cap Confidential, click here.

This is an excerpt from Cabot Small-Cap Confidential, which features little-known stocks with big potential. It offers a limited number of subscribers the opportunity to discover overlooked, low-priced stocks that have the potential to skyrocket. This advisory is best suited to experienced investors who embrace volatility.

Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.


Biogen is the market-share leader in treating multiple sclerosis.


One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >